Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial

RH Grimm; JJ McNeil; W Applegate; L Beilin; S Espinoza; C Johnston; B Kirpach; K Margolis; A Murray; MR Nelson; CM Reid; R Shah; E Storey; AM Tonkin; P Wilson; R Wolfe; RL Woods; W Abhayaratna; D Ames; L Cobiac; G Donnan; P Gibbs; R Head; H Krum; D Ives; AM Tonkin; M Jelnik; M Malik; J Williamson; C Eaton; J Weissfeld; F MacRae; LM Rodriguez; A Newman; J Demons; B Workman; E Wood; S Satterfield; JE Lockery; RC Shah; B Radziszewska; A Thomas; G Gill; C Jackson; M Kidd; G Russell

Journal article

Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial

RH Grimm, JJ McNeil, W Applegate, L Beilin, S Espinoza, C Johnston, B Kirpach, K Margolis, A Murray, MR Nelson, CM Reid, R Shah, E Storey, AM Tonkin, P Wilson, R Wolfe, RL Woods, W Abhayaratna, D Ames, L Cobiac Show all

Contemporary Clinical Trials | ELSEVIER SCIENCE INC | Published : 2013

DOI: 10.1016/j.cct.2013.09.014

University of Melbourne Researchers

Peter Gibbs Author Surgery - Royal Melbourne Hospital

David Ames Author Psychiatry

Grants

Funding Acknowledgements

ASPREE is registered on the International Standard Randomized Controlled Trial Number Register (ISRCTN83772183). ASPREE has received project grants from the National Institute on Aging, the National Health and Medical Research Council (Australia), Heart Foundation (Australia), the National Cancer Institute and the Victorian Cancer Agency (Australia). Bayer Pharma AG provides blinded aspirin and placebo. ASPREE has multiple IRB approvals in the US and Australia.